Translating Emergent Technologies into Novel Therapeutics: Tracing Complementarity and Co-evolution in the Cambridge–Boston Innovation Ecosystem
Maki Umemura
Abstract
This article traces the history of the life sciences business in the Cambridge–Boston area and explores how it became the global epicenter of the modern therapeutics industry. While business history scholarship on therapeutics is extensive, few have studied recent technological modalities—from therapeutic proteins to cell and gene therapies—or adopted a regional ecosystem perspective. Based on archival materials and oral histories, this research bridges these works and incorporates insights from the innovation ecosystems framework. It considers how dynamic interactions between an evolving network of complementary and interdependent actors, including therapeutics firms, universities, hospitals, and risk capital providers, enhanced innovative capacity. This perspective also illuminates how ecosystem strength derived from the co-evolution of actors—from universities restructuring technology transfer offices to academic scientists becoming entrepreneurs. The research further highlights the nonlinearity of innovation processes. It shows how an extraordinary interplay between structural advantage, serendipitous timing, and strategic actions cultivated an unparalleled capacity to translate emergent technologies into novel therapies.
1 citation
Evidence weight
Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40
| F · citation impact | 0.16 × 0.4 = 0.06 |
| M · momentum | 0.53 × 0.15 = 0.08 |
| V · venue signal | 0.50 × 0.05 = 0.03 |
| R · text relevance † | 0.50 × 0.4 = 0.20 |
† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.